Effects of arsenic trioxide (As2 O3 ) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance-Reference-Cited by-同舟云学术

Effects of arsenic trioxide (As2 O3 ) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance

Published:2001-06 Issue:6 Volume:66 Page:357-364
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Lehmann S.,Bengtzen S.,Paul A.,Christensson B.,Paul C.

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1034/j.1600-0609.2001.066006357.x/fullpdf

Reference39 articles.

1. Arsenic as a therapeutic agent in chronic myelogenous leukemia;Forker;JAMA,1931

2. Chronic arsenical poisoning during the treatment of chronic myeloid leukemia;Kandel;Arch Int Med,1937

3. The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia;Stephens;Ann Int Med,1936

4. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients;Niu;Blood,1999

5. Use of arsenic trioxide, (As2O3) in the treatment of acute promyelocytic leukemia (APL): II: Clinical efficacy and pharmacokinetics in patients at relapse;Shen;Blood,1997

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple roles of arsenic compounds in phase separation and membraneless organelles formation determine their therapeutic efficacy in tumors;Journal of Pharmaceutical Analysis;2024-08

2. Arsenic trioxide in pediatric cancer – a case series and review of literature;Pediatric Hematology and Oncology;2021-02-26

3. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases;Metallomics;2020-03

4. Circular RNAs: Potential Regulators of Treatment Resistance in Human Cancers;Frontiers in Genetics;2020-01-28

5. Suppression of NRF2–ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells;Toxicology and Applied Pharmacology;2016-02